Model
Digital Document
Publisher
Florida Atlantic University
Description
Ocular neovascularization (NV), the development of new blood vessels in the eye, occurs
when excessive vascular endothelial growth factor (VEGF) is produced. Eventually NV
may lead to photoreceptor loss and or blindness, as it does in age-related macular
degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy.
We tested the hypothesis that the anti-inflammatory cytokine, interleukin-10 (IL-10);
can reduce inflammation and block NV in the affected areas of the retina. The mouse
ROP model was used for this study of NV. Seven day old neonates stayed in 75% oxygen
for five days, then were given intraocular injection of IL-100 and NV was evaluated after
seven days in room air. Controls were uninjected contralateral eyes. IL-l 0 strongly
inhibited NV without affecting intra-retinal vessels. The selective inhibition of IL-10 on NV suggest a possible therapeutic use in infants with ROP, in diabetic retinopathy, and
possibly, in AMD where inflammation is a risk factor.
when excessive vascular endothelial growth factor (VEGF) is produced. Eventually NV
may lead to photoreceptor loss and or blindness, as it does in age-related macular
degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy.
We tested the hypothesis that the anti-inflammatory cytokine, interleukin-10 (IL-10);
can reduce inflammation and block NV in the affected areas of the retina. The mouse
ROP model was used for this study of NV. Seven day old neonates stayed in 75% oxygen
for five days, then were given intraocular injection of IL-100 and NV was evaluated after
seven days in room air. Controls were uninjected contralateral eyes. IL-l 0 strongly
inhibited NV without affecting intra-retinal vessels. The selective inhibition of IL-10 on NV suggest a possible therapeutic use in infants with ROP, in diabetic retinopathy, and
possibly, in AMD where inflammation is a risk factor.
Member of